Related Experiment Videos
Phototherapy of bladder cancer: dose/effect relationships
The Journal of Urology
|August 1, 1986
Summary
Hematoporphyrin derivative photodynamic therapy shows promise for bladder cancer. Optimal treatment involves small tumors, specific dihematoporphyrin ether concentrations, and extended light exposure for best results.
Area of Science:
- Oncology
- Photochemistry
- Biomedical Engineering
Background:
- Photodynamic therapy (PDT) using hematoporphyrin derivatives is clinically relevant for transitional cell carcinoma of the bladder.
- The precise mechanisms and optimal parameters of PDT for this cancer require further elucidation.
Purpose of the Study:
- To investigate the impact of dihematoporphyrin ether (DHE) concentration, light exposure duration, and initial tumor size on PDT efficacy.
- To identify optimal treatment conditions for a murine transitional cell tumor model.
Main Methods:
- Utilized a transplantable murine transitional cell tumor system.
- Varied dihematoporphyrin ether (DHE) concentration, light exposure duration (100-180 minutes), and initial tumor size (tumors < 6 mm diameter targeted).
Main Results:
- Tumor response was best in smaller tumors (less than 6 mm diameter).
- Optimal treatment involved 15 mg/kg DHE and 100-180 minutes of visible light exposure.
- A combination of small initial tumor size, higher DHE concentration, and longer light exposure correlated with the greatest tumor response.
Conclusions:
- Tumor size, DHE concentration, and light exposure duration are critical factors in PDT for transitional cell carcinoma.
- Tailoring these parameters can significantly improve treatment outcomes in preclinical models.
- Further research into PDT optimization is warranted for clinical application in bladder cancer.